Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah
Novartis announced that the US FDA has approved Kymriah™(tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, the first chimeric antigen receptor T cell (CAR-T) therapy,...
